Novel disease modifying medications for respiratory disease





Investment stage

Post-Series A

Enterprise Therapeutics is a drug discovery company focused on developing novel therapies for the treatment of respiratory diseases.

The Company's founders have significant expertise in drug discovery, respiratory biology and ion channel pharmacology and are focused on the discovery of novel disease modifying medications that target key drivers of respiratory disease pathology and progression in cystic fibrosis, chronic obstructive pulmonary disease (COPD) and severe asthma. These include targeting the underlying mechanisms of mucus congestion and lung dysfunction.

COPD is a chronic disease characterised by a progressive and irreversible decrease in lung function. Globally, COPD is reported to affect over 300 million people and in 2012 was the world’s third highest killer. The estimated economic cost of COPD is >$2 trillion.
CF is the most common lethal genetic disease of Caucasians with an estimated 100,000 patients worldwide. The average life expectancy, although improving, is approximately 40 years.

Related news

View all news